| scholarly article | Q13442814 |
| P50 | author | Annette Schmitt-Graeff | Q43376014 |
| P2093 | author name string | Hubert E Blum | |
| Florian Otto | |||
| Manfred Olschewski | |||
| Oliver G Opitz | |||
| Michael Geissler | |||
| Jan Harder | |||
| Brigitte Weinhold | |||
| Oliver Waiz | |||
| P2860 | cites work | Role of HER2/neu in tumor progression and therapy | Q28297138 |
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report | Q33250432 | ||
| Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer | Q33372640 | ||
| Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. | Q33961881 | ||
| Cholangiocarcinoma. | Q33990595 | ||
| Oncogene expression in cholangiocarcinoma and in normal hepatic development | Q34668400 | ||
| Review article: the modern diagnosis and therapy of cholangiocarcinoma | Q36455955 | ||
| HER2 testing in breast cancer: NCCN Task Force report and recommendations. | Q36524447 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial | Q36614800 | ||
| EGFR, HER2 and VEGF pathways: validated targets for cancer treatment | Q36947038 | ||
| ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions | Q38455863 | ||
| Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry | Q38456543 | ||
| Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues | Q38457973 | ||
| HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. | Q40107631 | ||
| Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. | Q40377343 | ||
| Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). | Q40809042 | ||
| Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma | Q42510917 | ||
| Expression of epidermal growth factor receptor in gastric carcinomas | Q44797497 | ||
| Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 | ||
| Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
| Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma | Q48480509 | ||
| c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 | ||
| Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. | Q53496139 | ||
| Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours | Q57003964 | ||
| Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract | Q71985964 | ||
| Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma | Q73653633 | ||
| Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study | Q74020609 | ||
| Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization | Q74375151 | ||
| c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma | Q77581743 | ||
| Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer | Q82241194 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4511-4517 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | EGFR and HER2 expression in advanced biliary tract cancer | |
| P478 | volume | 15 |
| Q33683102 | A genetic model for gallbladder carcinogenesis and its dissemination |
| Q37639577 | A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers |
| Q54222781 | A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. |
| Q26784091 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma |
| Q100525937 | Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer |
| Q34978321 | Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. |
| Q38993903 | Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer |
| Q39396785 | Biliary cancer: Utility of next-generation sequencing for clinical management |
| Q55364953 | Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. |
| Q42029380 | Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment |
| Q37660692 | Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells |
| Q54659121 | Detection of EGFR and COX-2 expression by immunohistochemical method on a tissue microarray section in lung cancer and biological significance |
| Q64992326 | Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q36370528 | Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma |
| Q36582547 | Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma |
| Q38812588 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). |
| Q89556171 | Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer |
| Q34180209 | Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma |
| Q91951546 | Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor |
| Q37794438 | Genetic abberations in gallbladder cancer |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q91728336 | HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q39040859 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? |
| Q54478596 | HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. |
| Q39137066 | Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. |
| Q37439940 | Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer |
| Q47398665 | JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma |
| Q39070009 | KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers |
| Q37307816 | Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer |
| Q42687892 | Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population |
| Q38734193 | Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. |
| Q35832274 | Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer |
| Q33557258 | Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer |
| Q34898080 | Pathological aspects of so called "hilar cholangiocarcinoma". |
| Q38331168 | Pathology of gallbladder carcinoma: current understanding and new perspectives |
| Q33994406 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. |
| Q39683530 | Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy |
| Q48203761 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
| Q51075580 | Prognostıc value of increased HER2 expression in cancers of pancreas and biliary tree. |
| Q33994814 | Recent advances in the regulation of cholangiocarcinoma growth |
| Q27693345 | Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. |
| Q39382611 | Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells |
| Q38849599 | Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation |
| Q34551877 | Systemic Therapy of Cholangiocarcinoma |
| Q35357793 | The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines |
| Q39422598 | The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines |
| Q38132400 | The role of epidermal growth factor receptor in cancer metastasis and microenvironment |
| Q26865749 | The significance of genetics for cholangiocarcinoma development |
Search more.